Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207

Authors:

Abstract
BACKGROUND Receptors for luteinizing hormone‐releasing hormone (LHRH) on human prostate cancers can be used for targeted chemotherapy with cytotoxic analogs of LHRH, such as AN‐207, which consists of superactive doxorubicin derivative 2‐pyrrolino doxorubicin (AN‐201) linked to carrier [d‐Lys6] LHRH. METHODS The effects of AN‐207 and AN‐201 were investigated in DU‐145 androgen independent and LuCaP‐35 androgen sensitive human prostate cancers xenografted into nude mice. Toxicity was evaluated by survival rates, changes in body weights, and leukocyte counts. LHRH receptors on DU‐145 and LuCaP‐35 tumors were evaluated by radioreceptor assays and RT‐PCR. The effects on apoptosis and cell proliferation were investigated by histology and evaluation of apoptotic oncogenes Bcl‐2 and Bax by Western Blot analysis. RESULTS AN‐207 inhibited growth of DU‐145 tumors significantly by 75% (P < 0.01) and LuCaP‐35 human prostate cancers by 80% (P < 0.01), and was less toxic than AN‐201. Receptors for LHRH were expressed on DU‐145 and LuCaP‐35 tumors. Blockade of LHRH receptors with LHRH agonist Triptorelin nullified the effects of AN‐207. Treatment with AN‐207, but not with AN‐201, decreased Bcl‐2/Bax ratio in DU‐145 tumors and Bcl‐2 in LuCaP‐35 tumors indicating an increase in apoptotic activity. AN‐207, but not AN‐201, decreased cell proliferation in both models. CONCLUSIONS Targeted chemotherapy with AN‐207 could be considered for treatment of advanced prostate cancer.

This publication has 37 references indexed in Scilit: